This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Centre Hôspitalier Universitaire De Poitiers, Centre National De La Recherche Scientifique, National Institute of Health and Medical Research. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 8 
1 out of 5,383 
1 out of 1,853 
Years Active: 2024
Title: André Herbelin: Innovator in Ischemia Reperfusion Injury Research
Introduction
André Herbelin is a notable inventor based in Poitiers, France. He has made significant contributions to the field of medical research, particularly in understanding and preventing ischemia reperfusion injury (IRI). His innovative work has implications for improving organ preservation and patient outcomes in various medical scenarios.
Latest Patents
André Herbelin holds a patent titled "Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33." This patent addresses the inflammation associated with IRI, which is characterized by leukocyte infiltration and renal tubular injury. The research identifies interleukin (IL)-33 as a critical factor in initiating tissue injury and amplifying the innate immune response during kidney ischemia-reperfusion in experimental models. The findings suggest that antagonists of IL-33 could be utilized to prevent IRI, thereby preserving renal function and reducing injury.
Career Highlights
Throughout his career, André Herbelin has worked with esteemed institutions such as the National Institute of Health and Medical Research (Institut National De La Santé Et De La Recherche Médicale) and the University Hospital Center of Poitiers (Centre Hospitalier Universitaire De Poitiers). His research has focused on the mechanisms of inflammation and injury in renal tissues, contributing to advancements in therapeutic strategies.
Collaborations
André has collaborated with notable colleagues, including Jean-Marc Gombert and Maroua Ferhat. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the medical field.
Conclusion
André Herbelin's work in the realm of ischemia reperfusion injury showcases his dedication to advancing medical science. His patent on IL-33 antagonists represents a significant step forward in the prevention of organ injury, highlighting the importance of innovative research in improving patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile